Probiodrug AG (Probiodrug) announced that it will be making two poster and two oral presentations at the upcoming Alzheimer's Association International Conference in Boston, MA July 13 - 18, 2013. These presentations will provide further insight into the rationale of targeting QC for the treatment of Alzheimer's disease. In addition, it will be presenting collaborative data on the efficacy[1] and safety in animal models of a passive immunotherapy[2] against Pyroglutamate-3 Abeta. Moreover, these presentations will provide results from first human studies with PQ912, a small molecule QC-inhibitor, in healthy elderly.
“The annual AAIC meeting is the world's largest gathering of Alzheimer's, dementia[3] and neuroscience specialists, making it an important forum for the discussion of novel approaches such as ours to the treatment of AD”
"The annual AAIC meeting is the world's largest gathering of Alzheimer's, dementia and neuroscience specialists, making it an important forum for the discussion of novel approaches such as ours to the treatment of AD," said Dr. Konrad Glund, CEO of Probiodrug. "We believe that QC inhibition has significant potential to slow the progression of AD and may even be able to reverse some of the cognitive deficits associated with the disease. PQ912, our experimental QC inhibitor, is currently in late Phase 1 clinical studies, and we look forward to testing this hypothesis as we advance the candidate through patient studies."
Presentation details
References
- ^ efficacy (www.news-medical.net)
- ^ immunotherapy (www.news-medical.net)
- ^ dementia (www.news-medical.net)
0 comments:
Post a Comment